Compare Cassava Sciences Inc (FLNA) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lowe`s Companies Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Lowe`s Companies Inc trades at $220.63 (market cap $122.73B). The key difference: Lowe`s Companies Inc is far larger — about 2570.3× Cassava Sciences Inc's market cap, and Lowe`s Companies Inc pays a 2.28% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LOW | |
|---|---|---|
Market Cap | $47.75M | $122.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $287.39 |
52-Week Low | $0.87 | $201.92 |
Enterprise Value | -$34.93M | $164.48B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Lowe's (LOW) trades at $223.35, up 2.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $257.69. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Fundamentals show solid profitability with a net income margin of 7.51% and a P/E ratio of 18.88, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights mixed sentiment, with some institutional selling but optimism around the Pro business segment.
The outlook for LOW is cautiously optimistic, supported by strong analyst buy ratings (60.79%) and a dividend payout. Key risks include competitive pressures, macroeconomic sensitivity, and high debt levels. The upcoming Q2 earnings report on August 19, 2026, will be critical for validating growth expectations and could drive near-term price movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
